A Randomized, Open-Label, Multicenter Study of Alimta (Pemetrexed) Plus VELCADE (Bortezomib) or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy

Trial Profile

A Randomized, Open-Label, Multicenter Study of Alimta (Pemetrexed) Plus VELCADE (Bortezomib) or Alimta Alone or VELCADE Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Antineoplastic Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Bortezomib (Primary) ; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms POINT-II
  • Sponsors Janssen-Cilag; Millennium
  • Most Recent Events

    • 15 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top